Allurion Q1 2025 Earnings Report
Key Takeaways
Allurion reported its first quarter 2025 financial results, showing reduced operating expenses and net operating loss, an improved gross margin, and progress toward FDA approval, while maintaining its full-year revenue guidance.
Reported first quarter 2025 revenue of $5.6 million.
Achieved a gross margin of 75% in Q1 2025, compared to 73% in the prior year.
Reduced total operating expenses by 37% year-over-year to $11.4 million.
Reduced net operating loss by 36% year-over-year to $7.3 million.
Allurion
Allurion
Forward Guidance
For 2025, Allurion expects revenue of approximately $30 million and a reduction of approximately 50% in operating expenses compared to 2024, aiming for increased efficiency and progress towards profitability. The company is also on track to complete its FDA PMA submission by the end of June 2025 and plans to start enrolling a prospective trial on the combination of the Allurion Program with low-dose GLP-1 medications this year.
Positive Outlook
- Maintaining 2025 revenue guidance at approximately $30 million.
- Anticipating a significant reduction in operating expenses (approx. 50% vs 2024).
- Expect to complete FDA PMA submission by the end of June 2025.
- Planning to start enrolling a prospective trial on the combination of the Allurion Program with low-dose GLP-1 medications in 2025.
- Focus on "Metabolically Healthy Weight Loss" with GLP-1 combination seen as a potential growth area.